Water soluble paclitaxel derivatives

Abstract

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

What is claimed is:  
     
         1 . A tumor tageting taxoid wherein when said tumor targeting taxoid is administered to a subject, the tumor targeting taxoid is uptaken into a tumor at a greater rate than free paclitaxel.  
     
     
         2 . The tumor targeting taxoid of  claim 1 , wherein said tumor is an ovarian tumor.  
     
     
         3 . A method of treating a condition responsive to a a therapeutic agent, comprising administering to a subject an effective amount of a tumor tageting taxoid wherein when said tumor targeting taxoid is administered to a subject, the tumor targeting taxoid is uptaken into a tumor at a greater rate than free paclitaxel.  
     
     
         4 . The method of  claim 3 , wherein the condition is selected from the group consisting of prostate, breast, ovarian, colon, leukemia and lung cancers, malignant melanoma, head and neck cancers, gastric cancer and Kaposi's sarcoma.  
     
     
         5 . The method of  claim 3 , wherein the condition is selected from the group consisting of prostate, breast, ovarian, colon, leukemia and lung cancers.  
     
     
         6 . The method of  claim 3 , wherein the condition is ovarian cancer.  
     
     
         7 . The method of  claim 3 , wherein the condition is colon cancer.  
     
     
         8 . The method of  claim 3 , wherein the condition is leukemia.  
     
     
         9 . The method of  claim 3 , wherein the condition is lung cancer.  
     
     
         10 . The method of  claim 3 , wherein the condition is prostate cancer.  
     
     
         11 . The method of  claim 3  wherein the drug is a chemotherapeutic or antiangiogenic drug.